ACE2 and COVID-19: Moreover, this important antibiotic lipoglycopeptide drug is also a novel candidate for COVID-19 treatment, where it blocks SARS-CoV-2 binding to its receptor ACE2 and reduces viral spread and pathogenesis in animal models [105].